|
|
|
| Human β-defensin-2 Enhances Anti-tumor Efficacy of Survivin-based Broad-spectrum DNA Vaccine in Mouse Tumor Model |
| LUO Yan-xi1, WANG Ming-long2, WANG Shi-bing3, SUN Ting1, XIE Tian4, YAN Hui1 |
1. Institute of Materia Medica, Hangzhou Medical Colle ge, Hangzhou 310013, China;
2. Department of Surgical Oncology, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China;
3. Molecular Diagnosis Laboratory, Zhejiang Provinc ial People s Hospital, People s Hospital of Hangzhou Medical College, Hangzhou 310013, China;
4. Holistic Inte grative Pharmacy Institutes, Hangzhou Normal University, Hangzhou 310013, China |
|
|
|
|
Abstract Objective: Malignant tumors greatly endanger and affect the quality of human life. Among antitumor biotherapy strategies, DNA vaccines hold promise in part because of their unique advantages. In this study, an effective broad-spectrum antitumor DNA vaccine expressing human survivin T34A dominant-negative mutant fused with human β-defensin-2 (HBD2) was investigated. Methods: The expression profiles of genes of interest were examined using western blotting, reverse transcription-polymerase chain reaction (RT-PCR), and enzyme-linked immunosorbent assay (ELISA) in vitro. The immune function of the fusion gene vaccine (FGV) was assessed in BALB/c mice, which included detection of serum antibody, spleen lymphocyte proliferation, interferon-gamma (IFN-γ) secretion, and lactate dehydrogenase (LDH) release. In vivo antitumor effects of FGV were examined in a mouse breast cancer (4T1) model, whereas in vitro effects were assessed using tumor cells derived from different origins. Caspase-3 activity in tumor cells was also assessed after vaccine transfection. Results: The FGV triggered humoral as well as cellular immune responses against survivin. It exhibited more potent inhibition of tumor growth as well as prolonged the survival of immunized mice compared to mice immunized with only either survivin T34A or HBD2 vaccines. In addition, FGV displayed stronger cytotoxicity against tumor cells derived from different origins compared to the other vaccines and facilitated increased caspase-3 activity in transfected tumor cells. Conclusion: The novel DNA vaccine consisting of a fusion of the universal tumor antigen survivin T34A mutant with molecular adjuvant HBD2 generates enhanced broad-spectrum antitumor efficacy against cancers derived from various origins.
|
|
Received: 05 August 2021
|
| Fund:Zhejiang Province Medical and Health Research Projects; grant number: 2014K Y A041; grant sponsor: Natural Science Foundation of Zhejiang Province; grant number: LGF19H160032 and 2015C03055; grant sponsor: the Key Programs of the National Natural Science Foundation of China; grant num-er: 81730108 |
|
Corresponding Authors:
YAN Hui, XIE Tian. E-mail: yanhui@zjams.com.cn (YAN Hui), xbs@dljg.sina.net (XIE Tian)
|
|
|
|
[1] HuoS, Liu L, Liu J, et al. Modulation of cancer immunotherapy effcacy by gut microbiota[J]. Discov Med, 2019, 27(147):93-100.
[2] Singh A, Trivedi P, Jain NK.Advances in siRNA delivery in cancer therapy[J]. Artif Cells Nanomed Biotechnol, 2018, 46(2):274-283.
[3] Zheng Meijun, Huang Jianhan, Tong Aiping, et al. Oncolytic viruses for cancer therapy: Barriers and recent advances[J] Mol Ther Oncolytics, 2019, 15:234-247.
[4] Mastrangelo MJ, Maguire HJ, Eisenlohr LC, et al. Intratumoral recombinant GM-CSF-encoding virus as gene thera-py in patients with cutaneous melanoma[J]. Cancer Gene Ther, 1999, 6 (5):409-422.
[5] Park BH, Hwang T, Liu TC, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial[J]. Lancet Onco, 2008, 9 (6):533-542.
[6] Heo J, Reid T, Ruo L, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer[J]. Nat Med, 2013, 19 (3):329-336.
[7] Lopes A, Vandermeulen G, Preat V.Cancer DNA vaccines: current preclinical and clinical developments and future perspectives[J]. J Exp Clin Cancer Res, 2019, 38(1): 146.
[8] Kartikasari A, Prakash MD, Cox M, et al. Therapeutic cancer vaccines-T cell responses and epigenetic modulation[J]. Front Immunol, 2018, 9:3109.
[9] Andersen MH, Svane IM, Becker JC, et al. The universal character of the tumor-associated antigen survivin[J]. Clin Cancer Res, 2007, 13(20):5991-5994.
[10] Krieg A, Baseras B, Tomezak M, et al. Role of survivin as prognostic and clinicopathological marker in gastric cancer: a meta-analysis[J]. Mol Biol Rep, 2013, 40 (9):5501-5511.
[11] Altieri DC.Survivin, cancer networks and pathway-directed drug discovery[J]. Nat Rev Cancer, 2008, 8(1):61-70.
[12] WangJ, Liu Z, Zhang D, et al. FL118, a novel survivin inhibitor, wins the battle against drug resistant and metastatic lung cancers through inhibition of cancer stem cell-like properties[J]. Am J Transl Res, 2017, 9(8): 3676-3686.
[13] Fang Qiu, Xia Zhao.In vivo antitumor activity of liposome plasmid DNA encoding mutant survivin-T34A in cervical cancer[J]. Mol Med Rep, 2018, 18(1) :841-847.
[14] Paduano F, Villa R, Pennati M, et al. Silencing of suvivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells[J]. Mol Cancer Ther, 2006, 5(1):179-186.
[15] Fenstermaker RA, Ciesielski MJ, Qiu J, et al. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma[J]. Cancer Immunol Immunother, 2016, 65(1):1339-1352.
[16] Circosta P, Vitaggio K, Eia AR, et al. Survivin-peptide vaccination elicits immune response after allogeneic non-myeloablative transplantation: a safe strategy to enhance the graft versus tumor effect[J]. Immunotherapy, 2018, 10(9):753-767.
[17] Peng XC, Yang L, Yang LP, et al. Efficient inhibition of murine breast cancer growth and metastasis by gene trans-ferred mouse survivin Thr34--> Ala mutant[J]. J Exp Clin Cancer Res, 2008, 27(1):46.
[18] Kameshima H, Tsuruma T, Torigoe T, et al. Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients[J]. Cancer Sci, 2011, 102(6):1181-1187.
[19] Braff MH.Antimicrobial peptides: an essential component of the skin defensive barrier[J]. Curr Top Microbiol Immunol, 2006, 306:91-110.
[20] Biragyn A, Ruffini PA, Leifer CA, et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2[J]. Science, 2002, 298(5595):1025-1029.
[21] Arya B, Belyakov IM, Yen-Hung C, et al. DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses[J]. Blood, 2002, 100(4):1153-1159.
[22] Sun T, Luo Y, Wang M, et al. Recombinant oncolytic vaccinia viruses expressing human beta-defensin 2 enhance anti-tumor immunity[J]. Mol Ther Oncolytics, 2019, 13:49-57.
[23] Villadangos JA, Young L. Antigen-presentation properties of plasmacytoid dendritic cells[J]. Immunity, 2008, 29 (3): 352-361.
[24] Wu X, Wu D, Lu Z, et al. A novel method for high-level production of TEV protease by superfolder GFP tag[J]. J Biomed Biotechnol, 2009, 2009:591923.
[25] Lapteva N, Aldrich M, Rollins L, et al. Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity[J]. Mol Ther, 2009, 17(9):1626.
[26] Shi L, Zhang L, Li C, et al. Dietary zine deficiency impairs humoral and cellular immune responses to BCG and ESAT-6/CFP-10 vaccination in offspring and adult rats[J]. Tuberculosis (Edinb), 2016, 97:86-96.
[27] Pierini S, Perales-Linares R, Uribe-Herranz M, et al. Trial watch: DNA-based vaccines for oncological indications[J]. Oncoimmunology, 2017, 6(12):e1398878.
[28] Velculescu VE, Madden SL, Zhang L, et al. Analysis of human transcriptomes[J]. Nat Genet, 1999, 23(4):387-388.
[29] O'Connor DS, Grossman D, Plescia J, et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin[J]. Proc Natl Acad Sci USA, 2000, 97(24):13103-13107.
[30] Flingai S, Czerwonko M, Goodman J, et al. Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants[J]. Front Immunol, 2013, 4:354.
[31] Zhu K, Qin H, Cha SC, Neelapu SS, et al. Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models[J] Vaccine, 2007, 25(46):7955-7961. |
|
|
|
